Breast Cancer

1. Clinical Overview

Summary

Breast cancer is the most common cancer in women worldwide, with approximately 1 in 8 women developing the disease during their lifetime. [1,2] It represents a heterogeneous group of malignancies characterized by distinct molecular subtypes that dictate treatment strategy and prognosis. The disease is classified primarily by hormone receptor status (ER, PR) and HER2 expression, which form the foundation of personalized therapy. [3]

Triple assessment—comprising clinical examination, imaging (mammography/ultrasound), and tissue diagnosis (core biopsy)—remains the diagnostic gold standard. [4] Management is multimodal, integrating surgery (breast-conserving or mastectomy), radiotherapy, and systemic therapy tailored to molecular subtype. Recent advances include CDK4/6 inhibitors for ER+ disease, dual HER2 blockade, PARP inhibitors for BRCA-mutated tumors, and immunotherapy for triple-negative breast cancer (TNBC). [5,6,7]

Population screening programs (mammography for women aged 50-70 in the UK) have reduced mortality by 20%, detecting cancers at earlier, more treatable stages. [8] Five-year survival exceeds 90% for early-stage disease but falls to 25-30% for metastatic presentations, underscoring the importance of early detection. [9]

Key Facts

• Incidence: Most common cancer in women; 55,000+ new cases annually in UK; 1 in 8 lifetime risk [1,2]
• Screening: NHS mammography ages 50-70 (every 3 years); 20% mortality reduction [8]
• Molecular Subtypes: ER+/PR+ (70%), HER2+ (15-20%), Triple-negative (15%) [3]
• Triple Assessment: Clinical exam + Imaging + Histopathology (sensitivity > 95%) [4]
• Surgery: Wide local excision (WLE) vs Mastectomy (equivalent survival with adjuvant RT) [10]
• Systemic Therapy: Subtype-driven: Endocrine (ER+), Anti-HER2 (HER2+), Chemotherapy (TNBC) [5,6]
• Prognosis: 5-year survival 95% (Stage I), 25-30% (Stage IV) [9]
• Genetic Risk: BRCA1 (55-65% lifetime risk), BRCA2 (45% risk) [11]

Clinical Pearls

"Receptor Status Drives Everything": ER/PR positive = Endocrine therapy backbone. HER2+ = Trastuzumab-based regimens. Triple-negative = Chemotherapy ± immunotherapy. Always confirm receptor status before planning treatment.

"Triple Assessment is Non-Negotiable": Any breast lump requires all three components. Sensitivity of combined assessment > 95%; individual modalities alone are insufficient. [4]

"Skin Changes = Red Flag": Peau d'orange (dermal lymphatic invasion), skin dimpling (Cooper's ligament tethering), nipple retraction, or ulceration demand urgent evaluation for locally advanced or inflammatory breast cancer.

"CDK4/6 Inhibitors Transform ER+ Disease": Palbociclib, ribociclib, abemaciclib added to endocrine therapy nearly double progression-free survival (PFS) in metastatic ER+ disease. Now standard first-line. [5,12]

"De-escalation is Evidence-Based": Sentinel lymph node biopsy (SLNB) has replaced routine axillary clearance. Hypofractionated radiotherapy (15-16 fractions) is now standard. Avoid overtreatment. [13,14]

"Inflammatory Breast Cancer Mimics Infection": Always consider IBC in "mastitis" that doesn't respond to antibiotics. Peau d'orange, erythema, warmth, and rapid onset. Urgent biopsy required.

---

2. Epidemiology

Incidence and Prevalence

Breast cancer is the most frequently diagnosed cancer globally, with over 2.3 million new cases annually worldwide. [1] In the United Kingdom, approximately 55,000 new cases are diagnosed each year, with incidence rates having increased steadily over the past four decades due to improved screening, aging populations, and lifestyle factors. [2] Despite rising incidence, mortality has declined by 40% since the 1980s, attributed to earlier detection and improved systemic therapies. [9]

Key Statistics:

• Lifetime Risk: 1 in 8 women (12.5%) will develop breast cancer [2]
• Age-Specific Incidence: Rare below age 30; incidence rises sharply after menopause, peaking at 55-65 years [2]
• Male Breast Cancer: Accounts for less than 1% of all cases; often presents later due to delayed awareness [15]
• Mortality: Second leading cause of cancer death in women (after lung cancer) [9]

Demographics

Risk Factors

High-Risk Factors (Relative Risk > 4)

Moderate-Risk Factors (Relative Risk 1.5-4)

Protective Factors

• Breastfeeding: 4-5% risk reduction per 12 months of lactation [18]
• Early first pregnancy (less than 25 years): Breast differentiation effect
• Physical activity: 20-40% risk reduction with regular exercise [19]
• Oophorectomy before menopause: 50% reduction (BRCA carriers: 85% reduction) [11]

Genetic Predisposition

Approximately 5-10% of breast cancers are hereditary, linked to germline mutations in DNA repair genes. [11]

Genetic Testing Indications:

• Diagnosis less than 40 years
• Triple-negative breast cancer less than 60 years
• Male breast cancer
• Bilateral breast cancer
• ≥2 first-degree relatives with breast/ovarian cancer
• Ashkenazi Jewish ancestry (BRCA founder mutations)

---

3. Pathophysiology

Cell of Origin

Most breast cancers arise from the terminal duct-lobular unit (TDLU), the functional milk-producing structure comprising terminal ducts and lobules. Malignant transformation follows a stepwise accumulation of genetic and epigenetic alterations, progressing from hyperplasia → atypical hyperplasia → carcinoma in situ → invasive carcinoma. [20]

Histological Classification

Special Entities:

• Paget's Disease of Nipple: Malignant cells (Paget cells) in nipple epidermis; associated with underlying DCIS/invasive cancer in 95%
• Phyllodes Tumor: Fibroepithelial neoplasm; most benign, 10-20% malignant; local recurrence risk

Molecular Subtypes

Breast cancer molecular classification, based on gene expression profiling, has revolutionized treatment. [3] Surrogate immunohistochemical (IHC) markers approximate intrinsic subtypes:

Ki67 Proliferation Index: Nuclear protein expressed in proliferating cells; ≥20% defines high proliferative activity, guiding chemotherapy decisions in ER+ disease.

Molecular Biology

Estrogen Receptor (ER) Pathway

• ER-α drives transcription of proliferation genes (cyclin D1, c-Myc)
• Positive in 70% of breast cancers
• Target for endocrine therapy (tamoxifen, aromatase inhibitors)
• Resistance mechanisms: ESR1 mutations, cross-talk with growth factor receptors [21]

HER2 Pathway

• HER2 (ERBB2) gene amplification or protein overexpression (IHC 3+ or FISH ratio ≥2.0)
• Constitutive receptor tyrosine kinase activation → MAPK/PI3K signaling
• Historically poor prognosis; transformed by trastuzumab, pertuzumab, TDM-1, T-DXd [6]

Triple-Negative Breast Cancer (TNBC)

• Lacks ER, PR, HER2 expression
• 70-80% overlap with basal-like subtype
• Enriched in BRCA1 mutations (60% of BRCA1 cancers are TNBC)
• High tumor mutational burden → responsive to immunotherapy [7]
• Subtypes: BL1 (immunosuppressed), BL2 (immune-activated), LAR (luminal androgen receptor), M (mesenchymal)

Tumor-Infiltrating Lymphocytes (TILs)

• Stromal TILs ≥10% associated with improved outcomes in TNBC and HER2+ disease [22]
• Predictive biomarker for immunotherapy response

Mechanisms of Spread

Local Invasion

• Direct extension through breast parenchyma
• Invasion of Cooper's ligaments → skin tethering/dimpling
• Pectoralis muscle/chest wall invasion → T4 disease

Lymphatic Spread

• Axillary nodes (Levels I-III): Most common first site (75%)
  • "Level I: Lateral to pectoralis minor"
  • "Level II: Behind pectoralis minor"
  • "Level III: Medial to pectoralis minor (infraclavicular)"
• Internal mammary nodes: 20-30% (medial tumors); poor prognosis marker
• Supraclavicular nodes: Classified as N3 (regional) since AJCC 8th edition

Hematogenous Spread (Distant Metastases)

Micrometastatic Disease: Disseminated tumor cells present in bone marrow/circulation at diagnosis in 20-40%, explaining late relapses (ER+ disease can recur > 10 years post-treatment).

---

4. Clinical Presentation

Symptomatic Presentation

Approximately 70% of breast cancers present symptomatically (30% screen-detected in UK). [8]

Clinical Examination Findings

Features Favoring Malignancy

Clinical Staging (Pre-Treatment)

Tumor (T) Assessment:

• T1: ≤2 cm (T1 a: ≤0.5 cm, T1 b: 0.5-1 cm, T1 c: 1-2 cm)
• T2: 2-5 cm
• T3: > 5 cm
• T4: Chest wall/skin invasion (T4 a: chest wall, T4 b: skin ulceration/nodules, T4 c: both, T4 d: inflammatory)

Nodal (N) Assessment:

• N0: No palpable nodes
• N1: Mobile ipsilateral axillary nodes
• N2: Fixed/matted ipsilateral axillary nodes, or clinically apparent internal mammary nodes
• N3: Ipsilateral infraclavicular/supraclavicular nodes

Special Clinical Scenarios

Inflammatory Breast Cancer (IBC)

Definition: Clinical-pathologic entity characterized by rapid onset erythema, edema, and peau d'orange involving ≥1/3 of breast, with dermal lymphatic invasion on biopsy.

Diagnostic Criteria:

• Erythema covering ≥1/3 breast
• Peau d'orange (orange peel appearance)
• Warmth, tenderness
• Rapid progression (less than 6 months)
• Biopsy: Dermal lymphatic tumor emboli

Prognosis: Historically dismal (5-year survival less than 10%); improved to 40-50% with multimodal therapy (neoadjuvant chemotherapy + surgery + radiotherapy). [23]

Differential: Mastitis (responds to antibiotics within 48-72 hours), abscess, radiation recall

Paget's Disease of the Nipple

Presentation: Unilateral nipple eczema, scaling, crusting, erosion; may extend to areola. Often mistaken for dermatitis.

Pathophysiology: Migration of malignant ductal cells (Paget cells) into nipple epidermis; 95% have underlying DCIS or invasive carcinoma.

Diagnosis: Nipple skin biopsy (punch or shave) → Paget cells (large, pale, vacuolated cytoplasm; PAS-positive mucin)

Imaging: MRI to assess extent of underlying disease (often multifocal)

Male Breast Cancer

Epidemiology: 1% of all breast cancers; median age 68 years (5-10 years older than females)

Risk Factors: BRCA2 mutation (6% lifetime risk), Klinefelter syndrome (XXY), obesity, liver disease (hyperestrogenism)

Presentation: Subareolar mass, nipple discharge/retraction (central location); often delayed diagnosis

Pathology: 90% ER+; HER2+ in 10%; TNBC rare

Treatment: Mastectomy (breast conservation rarely feasible); systemic therapy as per female guidelines

Pregnancy-Associated Breast Cancer (PABC)

Definition: Diagnosed during pregnancy or within 12 months postpartum

Incidence: 1 in 3,000 pregnancies; most common cancer in pregnancy

Challenges: Delayed diagnosis (physiological breast changes); imaging limitations (avoid ionizing radiation in 1st trimester); chemotherapy teratogenicity

Management:

• Imaging: Ultrasound first-line; MRI without gadolinium if needed
• Surgery: Safe in all trimesters
• Chemotherapy: Relatively safe in 2nd/3rd trimester (avoid 1st trimester, last 3 weeks before delivery)
• Radiotherapy: Deferred until postpartum
• Endocrine therapy: Contraindicated (tamoxifen teratogenic)

Prognosis: Stage-for-stage similar to non-pregnant; often diagnosed at later stage

---

5. Clinical Examination

Inspection (Patient Sitting, Arms at Sides, Then Raised, Then Hands on Hips)

Look For:

• Asymmetry: Size, contour, level
• Skin Changes: Erythema, peau d'orange, dimpling, ulceration, satellite nodules
• Nipple: Deviation, retraction, inversion (new vs longstanding), eczema, discharge
• Visible Mass: Bulge or contour abnormality
• Vascular Pattern: Prominent veins (high flow tumors)
• Chest Wall: Previous scars, radiation changes

Maneuvers:

• Arms Raised: Accentuates skin tethering (Cooper's ligament)
• Hands on Hips (Pectoral Contraction): Reveals fixation to pectoralis fascia/muscle

Palpation (Patient Supine, Arm Above Head)

Systematic Examination:

• Four Quadrants + Subareolar: Use pads of 2nd-4th fingers; concentric circles or vertical strips
• Tail of Spence: Axillary tail (upper-outer quadrant extension)
• Chest Wall: Assess mobility (superficial vs deep fixation)

Lump Characteristics (if Present):

Lymph Node Examination

Axillary Nodes

• Technique: Support patient's arm; examine with contralateral hand
• Groups: Central, lateral (against humerus), pectoral (against chest wall), subscapular (posterior), apical (infraclavicular)
• Abnormal Features: Hard, fixed, matted, > 1 cm

Supraclavicular/Infraclavicular Nodes

• Palpate from behind patient
• Presence = N3 disease

Cervical Nodes

• Rare; suggests advanced disease

Bilateral Examination

Always examine contralateral breast (5-10% synchronous bilateral cancers)

---

6. Investigations

Triple Assessment (Diagnostic Triad)

The triple assessment combines three modalities to achieve > 95% diagnostic accuracy, reducing false positives/negatives. [4]

1. Clinical Examination

See above section.

2. Imaging

Mammography

Indications:

• Symptomatic patients ≥40 years
• Screening (asymptomatic 50-70 years)
• Follow-up post-treatment

Views:

• Standard: Craniocaudal (CC) + Mediolateral oblique (MLO)
• Additional: Spot compression, magnification (microcalcifications)

Malignant Features:

• Mass: Spiculated, irregular, high density
• Microcalcifications: Fine, linear/branching (casting), clustered (DCIS)
• Architectural Distortion: Radiating spicules without central mass
• Asymmetric Density: Compared to contralateral breast

BI-RADS Classification:

Limitations:

• Reduced sensitivity in dense breasts (young, premenopausal)
• Radiation exposure (minimal: 0.4 mSv per study)

Ultrasound

Indications:

• First-line imaging less than 40 years (dense breast tissue)
• Characterization of mammographic abnormalities
• Axillary node assessment
• Biopsy guidance

Malignant Features:

• Irregular hypoechoic mass
• Taller-than-wide orientation (AP > transverse)
• Posterior acoustic shadowing
• Thick echogenic halo
• Microcalcifications within mass

Benign Features:

• Wider-than-tall orientation
• Circumscribed margins
• Posterior acoustic enhancement (cyst)
• Thin echogenic capsule

Magnetic Resonance Imaging (MRI)

Indications:

• Screening: High-risk patients (BRCA carriers, > 20% lifetime risk) [16]
• Staging: Lobular carcinoma (often multicentric/multifocal); discordant clinical/imaging findings
• Neoadjuvant Response Assessment: Monitor tumor response to chemotherapy
• Breast Implants: Silicone rupture evaluation
• Occult Primary: Axillary nodal metastases with unknown primary

Malignant Features:

• Irregular enhancing mass
• Rim enhancement
• Washout kinetics (rapid early enhancement, delayed washout)
• Non-mass enhancement (clumped, linear ductal)

Limitations:

• High sensitivity (90%) but lower specificity (70-80%); false positives common
• Requires gadolinium contrast (contraindicated in severe renal impairment)
• Expensive; not widely available for routine use

Molecular Breast Imaging (MBI) / Contrast-Enhanced Mammography (CEM)

• Emerging modalities for dense breasts
• Higher sensitivity than standard mammography

3. Tissue Diagnosis

Core Needle Biopsy (CNB)

Technique:

• 14-gauge needle (minimum)
• Ultrasound or stereotactic (mammographic) guidance
• ≥4 cores recommended

Advantages:

• Histological architecture preserved (distinguishes invasive vs in situ)
• Receptor status (ER, PR, HER2, Ki67) obtained pre-operatively
• Planning neoadjuvant therapy

Pathology Report:

Fine Needle Aspiration (FNA)

• Cytology only (no architecture)
• Largely replaced by CNB
• Still used for axillary node assessment (rapid, high specificity)

Vacuum-Assisted Biopsy (VAB)

• Larger tissue samples (8-11 gauge)
• Used for mammographic microcalcifications (DCIS)
• Complete excision of small lesions possible

Staging Investigations (Post-Diagnosis)

Performed if high risk of metastases (≥4 positive nodes, T3/T4 tumors, symptomatic, inflammatory breast cancer).

Baseline Blood Tests:

• FBC (cytopenias suggest marrow infiltration)
• LFTs (elevated in liver metastases)
• Calcium (hypercalcaemia in bone metastases)
• Tumor markers (CA 15-3, CEA): Not diagnostic; used for monitoring metastatic disease

---

7. Management

Overview

Breast cancer management is multimodal and subtype-driven, integrating:

1. Local Therapy: Surgery ± Radiotherapy
2. Systemic Therapy: Chemotherapy, Endocrine therapy, Anti-HER2 therapy, Immunotherapy
3. Supportive Care: Psychosocial support, survivorship, rehabilitation

Treatment decisions guided by:

• Stage (TNM)
• Molecular Subtype (ER, PR, HER2, Ki67)
• Patient Factors (Age, comorbidities, preferences)
• Tumor Biology (Grade, genomic assays)

Staging (AJCC TNM 8th Edition)

Tumor (T)

• Tis: DCIS or Paget's disease
• T1: ≤2 cm (T1 mi: ≤0.1 cm microinvasion; T1 a: 0.1-0.5 cm; T1 b: 0.5-1 cm; T1 c: 1-2 cm)
• T2: 2-5 cm
• T3: > 5 cm
• T4: Chest wall/skin involvement (T4 a: chest wall; T4 b: skin ulceration/nodules/edema; T4 c: both; T4 d: inflammatory)

Nodes (N) - Pathological

• pN0: No nodal metastases
• pN1mi: Micrometastases (0.2-2 mm)
• pN1: 1-3 positive axillary nodes
• pN2: 4-9 positive axillary nodes, or clinically apparent internal mammary nodes
• pN3: ≥10 axillary nodes, or infraclavicular/supraclavicular nodes, or ipsilateral internal mammary + axillary nodes

Metastasis (M)

• M0: No distant metastases
• M1: Distant metastases (includes ipsilateral supraclavicular nodes in AJCC 6th; now N3)

Anatomic Stage Groups (Simplified)

Note: AJCC 8th edition incorporates biological factors (ER, PR, HER2, grade) into prognostic stage groups, which may differ from anatomic stage.

Surgical Management

Breast Surgery

┌────────────────────────────────────────────────────────┐
│   SURGICAL OPTIONS FOR INVASIVE BREAST CANCER          │
├────────────────────────────────────────────────────────┤
│                                                        │
│  BREAST-CONSERVING SURGERY (BCS / LUMPECTOMY / WLE):   │
│  • Tumor ≤5 cm with adequate breast:tumor ratio        │
│  • Unifocal disease                                    │
│  • Requires clear margins (≥2 mm for invasive, ≥2 mm   │
│    for DCIS per UK guidelines; "no ink on tumor" USA)  │
│  • MANDATORY adjuvant whole-breast radiotherapy        │
│  • Equivalent survival to mastectomy [10]              │
│  • Re-excision rate: 20-30%                            │
│                                                        │
│  MASTECTOMY:                                            │
│  • Multicentric disease (> 1 quadrant)                  │
│  • Large tumor:breast ratio (cosmetically unfavorable) │
│  • Contraindication to radiotherapy (pregnancy,        │
│    previous RT, connective tissue disease)             │
│  • Patient preference (avoid RT, reduce recurrence)    │
│  • Inflammatory breast cancer (post-neoadjuvant)       │
│  • BRCA carriers (risk-reducing bilateral mastectomy)  │
│  • Immediate or delayed reconstruction offered         │
│                                                        │
│  ONCOPLASTIC SURGERY:                                   │
│  • Combines oncologic resection with plastic surgery   │
│  • Volume displacement (therapeutic mammoplasty) or    │
│    replacement (flaps)                                 │
│  • Allows wider excisions with superior cosmesis       │
│                                                        │
└────────────────────────────────────────────────────────┘

Key Trials:

• NSABP B-06, Milan I, EORTC 10801: BCS + RT = Mastectomy for survival (20-year follow-up) [10]

Axillary Surgery

Paradigm Shift: De-escalation from routine axillary lymph node dissection (ALND) to sentinel lymph node biopsy (SLNB). [13]

Sentinel Lymph Node Biopsy (SLNB):

• Technique: Radiotracer (Tc-99m) ± blue dye injected; first draining node(s) identified and excised
• Indication: Clinically node-negative (cN0) patients
• Sensitivity: 95% for identifying nodal metastases
• False Negative Rate: 5-10%
• Morbidity: Lymphedema less than 5% (vs 20-40% with ALND)

SLNB Positive: When to Proceed to ALND?

Current Practice:

• Omit ALND if: BCS + whole breast RT, 1-2 macrometastases (or any micrometastases), cT1-2
• Perform ALND if: ≥3 positive SLNs, mastectomy without RT, extranodal extension, neoadjuvant chemotherapy (unless post-treatment negative SLNB)

Reconstruction

Timing:

• Immediate: At time of mastectomy; superior cosmesis, psychological benefit
• Delayed: After adjuvant therapy; allows RT without implant complications

Types:

• Implant-Based: Tissue expander → permanent implant; single-stage (direct-to-implant with ADM)
• Autologous Flaps: DIEP (deep inferior epigastric perforator), latissimus dorsi, TRAM; better long-term aesthetic outcome; higher complication rate
• Nipple Reconstruction: Tattooing, local flaps (delayed procedure)

Contraindications to Immediate Reconstruction:

• Inflammatory breast cancer (high recurrence risk)
• Locally advanced disease requiring post-mastectomy RT (unless autologous flap planned)

Radiotherapy

Indications

Hypofractionation: Shorter courses (15-16 fractions vs 25) with equivalent efficacy and toxicity; now standard per START A/B, UK FAST trials. [14]

Partial Breast Irradiation (PBI): Investigational; tumor bed only (IORT, brachytherapy); for low-risk, older patients.

Toxicity

• Acute: Skin erythema, desquamation, fatigue
• Late: Fibrosis, lymphedema, pneumonitis (less than 2%), cardiac toxicity (left-sided; reduced with modern techniques), secondary malignancy (rare)

Systemic Therapy

Systemic therapy is subtype-driven. Adjuvant (post-surgery) or neoadjuvant (pre-surgery) timing chosen based on clinical scenario.

1. Endocrine Therapy (ER+ Disease)

Premenopausal:

• Tamoxifen 20 mg daily × 5-10 years (ATLAS, aTTom: 10 years superior) [24]
  • SERM (selective estrogen receptor modulator)
  • "Side effects: Hot flushes, VTE (1-2%), endometrial cancer (0.5%/year)"
• Ovarian Suppression + Aromatase Inhibitor (AI): SOFT/TEXT trials: GnRH agonist (goserelin) + exemestane superior to tamoxifen in high-risk premenopausal women [25]

Postmenopausal:

• Aromatase Inhibitors (AI) × 5 years: Anastrozole, letrozole, exemestane
  • Superior to tamoxifen (ATAC, BIG 1-98 trials)
  • "Side effects: Arthralgia, osteoporosis (monitor BMD), cardiovascular events"
• Sequential Therapy: Tamoxifen 2-3 years → AI 2-3 years (or vice versa)

High-Risk Disease (Node+):

• Extended Therapy: AI beyond 5 years (MA.17 trial: letrozole 10 years reduces recurrence)

Resistance Mechanisms:

• ESR1 mutations (acquired)
• Cross-talk with HER2, PI3K pathways

2. CDK4/6 Inhibitors (Advanced ER+ Disease)

Revolutionized metastatic ER+ breast cancer management. [5,12]

Mechanism: Inhibit CDK4/6 → block Rb phosphorylation → G1 cell cycle arrest

Toxicity: Neutropenia (rarely febrile), diarrhea (abemaciclib), QTc prolongation (ribociclib)

Adjuvant Use: Abemaciclib approved for high-risk early ER+ disease (≥4 nodes or 1-3 nodes + high-risk features)

3. HER2-Targeted Therapy (HER2+ Disease)

Standard Adjuvant (Early HER2+):

• AC-TH (Doxorubicin/Cyclophosphamide × 4 → Paclitaxel/Trastuzumab × 12 weeks, then Trastuzumab to 1 year)
• TCH (Docetaxel/Carboplatin/Trastuzumab × 6 → Trastuzumab to 1 year) if contraindication to anthracyclines

Standard 1st-Line Metastatic:

• Pertuzumab + Trastuzumab + Taxane (CLEOPATRA: median OS 56.5 months) [6]

Cardiotoxicity: LVEF monitoring required (baseline, every 3 months); risk 2-5% (reversible in most)

4. Chemotherapy

Indications:

• Triple-negative breast cancer (all stages)
• HER2+ disease (with anti-HER2 therapy)
• ER+ disease with high-risk features (node+, high grade, high Ki67, low ER)

Adjuvant Regimens:

Neoadjuvant Chemotherapy:

• Indications: Locally advanced (downstage to operability), triple-negative, HER2+, desire breast conservation
• Regimens: Same as adjuvant (AC-T + Trastuzumab/Pertuzumab if HER2+)
• Pathological Complete Response (pCR): No invasive cancer in breast/nodes; surrogate for improved survival
  • pCR rates: TNBC 40-50%, HER2+ 60-70% (with dual HER2 blockade), ER+ 10-20%

Genomic Assays (ER+ Disease): Predict chemotherapy benefit

• Oncotype DX (21-gene): Recurrence Score less than 26 → omit chemo (TAILORx trial)
• MammaPrint (70-gene): Low-risk → omit chemo (MINDACT trial)

Toxicity:

• Anthracyclines: Cardiomyopathy (dose-dependent; lifetime limit 450-550 mg/m² doxorubicin), alopecia, nausea
• Taxanes: Peripheral neuropathy, myalgia, hypersensitivity
• Cyclophosphamide: Hemorrhagic cystitis, infertility

5. Immunotherapy (Triple-Negative Breast Cancer)

Mechanism: PD-1/PD-L1 blockade restores T-cell anti-tumor immunity

Biomarker: PD-L1 IHC (CPS ≥10 for pembrolizumab; IC ≥1% for atezolizumab)

Toxicity: Immune-related AEs (colitis, pneumonitis, thyroiditis, hepatitis)

6. PARP Inhibitors (BRCA-Mutated)

Mechanism: Synthetic lethality in BRCA-deficient (homologous recombination-deficient) tumors

Toxicity: Myelosuppression, nausea, fatigue, rare MDS/AML

Treatment by Stage

Stage 0 (DCIS)

Management:

• BCS + RT (whole breast 50 Gy) OR Mastectomy (no RT)
• Endocrine therapy (tamoxifen × 5 years) if ER+ (reduces ipsilateral and contralateral risk by 50%)
• No axillary surgery (SLNB only if mastectomy or microinvasion suspected)

Prognosis: 10-year breast cancer mortality less than 2% (essentially curable)

Stage I-II (Early Breast Cancer)

Locoregional:

• Surgery (BCS vs mastectomy) + SLNB
• RT (post-BCS always; post-mastectomy if high-risk)

Systemic:

• ER+ HER2-: Endocrine ± chemo (genomic assays guide)
• ER+ HER2+: Chemo + Trastuzumab + Endocrine
• ER- HER2+: Chemo + Trastuzumab (± Pertuzumab if node+)
• Triple-negative: Chemo ± Pembrolizumab (if high-risk)

Stage III (Locally Advanced)

Approach:

• Neoadjuvant chemotherapy (± anti-HER2 ± immunotherapy) × 4-6 cycles
• Surgery (mastectomy usually; BCS if excellent response)
• RT (chest wall + nodal basins)
• Adjuvant systemic therapy (complete planned duration)

Special Case - Inflammatory Breast Cancer:

• Neoadjuvant chemo + anti-HER2 (if HER2+) → Mastectomy (BCS contraindicated) → RT (mandatory) → Adjuvant systemic therapy

Stage IV (Metastatic)

Philosophy: Palliative intent; prolong survival and quality of life

Locoregional Therapy:

• Surgery/RT for intact primary: May improve outcomes in oligometastatic disease (controversial)

Systemic Therapy (by Subtype):

• ER+ HER2-: Endocrine + CDK4/6 inhibitor (1st-line); sequential endocrine or chemo on progression [5]
• ER+ HER2+: Pertuzumab + Trastuzumab + Taxane → T-DM1 → T-DXd → Capecitabine + Lapatinib
• ER- HER2+: Pertuzumab + Trastuzumab + Taxane → T-DM1 → T-DXd [27]
• Triple-negative: Pembrolizumab + Chemo (if PD-L1+) → Carboplatin → Capecitabine; PARP inhibitor if BRCA-mutated

Site-Directed Therapy:

• Bone metastases: Bisphosphonates (zoledronic acid) or denosumab (reduce skeletal events 30-40%) + RT for pain
• Brain metastases: Stereotactic radiosurgery (oligometastatic) or whole-brain RT; tucatinib-based regimen (HER2+)
• Liver metastases: Systemic therapy; rarely resectable

Median OS (Metastatic):

• ER+ HER2-: 3-5 years (with modern CDK4/6 inhibitors)
• HER2+: 4-5 years (with dual HER2 blockade)
• Triple-negative: 12-18 months

---

8. Complications

Complications of Disease

Complications of Treatment

Surgical

• Seroma (30%): Aspiration if symptomatic
• Infection (5-10%): Antibiotics ± drainage
• Hematoma (2-5%): Surgical evacuation if expanding
• Lymphedema (5% SLNB, 20-40% ALND): Compression, physiotherapy
• Chronic pain (10-20%): Neuropathic (intercostobrachial nerve injury); gabapentin, amitriptyline
• Cosmetic dissatisfaction (variable): Oncoplastic techniques reduce risk

Radiotherapy

• Acute: Dermatitis (90%), fatigue (60%)
• Late: Fibrosis (20%), lymphedema (10%), pneumonitis (less than 2%), cardiac toxicity (left-sided; reduced with modern techniques), rib fracture (less than 1%), secondary malignancy (sarcoma, lung cancer; rare)

Chemotherapy

• Hematologic: Neutropenia (febrile neutropenia 5-10%), anemia, thrombocytopenia
• GI: Nausea/vomiting (reduced with modern antiemetics), mucositis, diarrhea
• Cardiac: Anthracycline cardiomyopathy (dose-dependent; 2-5% at standard doses); trastuzumab cardiotoxicity (2-5%, reversible)
• Neurologic: Taxane peripheral neuropathy (30-50%; often persistent)
• Reproductive: Chemotherapy-induced amenorrhea (age-dependent; 80% if > 40 years)
• Alopecia: Universal with anthracyclines/taxanes; reversible
• Secondary malignancy: Acute leukemia (0.5-1% with anthracyclines/alkylating agents)

Endocrine Therapy

• Tamoxifen: Hot flushes (60%), VTE (1-2%), endometrial cancer (0.5%/year), cataracts
• Aromatase Inhibitors: Arthralgias (50%), osteoporosis/fractures (annual DEXA monitoring), cardiovascular events

---

9. Prognosis & Outcomes

Survival by Stage

Source: SEER database, UK cancer statistics [9]

Prognostic Factors

Favorable Prognosis

• Small tumor (T1)
• Node-negative (N0)
• ER/PR positive (endocrine-responsive)
• HER2 positive (with anti-HER2 therapy)
• Low grade (Grade 1)
• Low Ki67 (less than 20%)
• Tubular/mucinous histology
• High TILs (TNBC, HER2+)

Poor Prognosis

• Large tumor (T3-4)
• Node-positive (especially ≥4 nodes)
• Triple-negative (limited systemic options)
• HER2 positive (untreated; good with therapy)
• High grade (Grade 3)
• High Ki67 (≥20%)
• Lymphovascular invasion (LVI)
• Inflammatory breast cancer

Recurrence Risk

Early ER+ Disease: Late relapses common (peak 5-7 years; continues > 10 years)

• 15-year recurrence: 13% (node-negative) to 40% (≥4 nodes)
• Extended endocrine therapy reduces late recurrence

Triple-Negative: Early relapses (peak 1-3 years); plateau after 5 years

• 5-year recurrence: 25-40% (depending on stage)
• Late relapses rare

HER2+: Intermediate pattern; reduced recurrence with modern anti-HER2 therapy

Gene Expression Profiling

Utility: Reduce chemotherapy overtreatment in intermediate-risk ER+ disease

Quality of Life and Survivorship

Long-Term Effects:

• Physical: Lymphedema, neuropathy, arthralgias, sexual dysfunction, cognitive impairment ("chemo brain")
• Psychological: Anxiety, depression, fear of recurrence (30-50%)
• Social: Body image issues, fertility concerns, financial toxicity

Survivorship Care:

• Annual mammography (ipsilateral + contralateral)
• Clinical follow-up every 3-6 months × 5 years, then annually
• Bone density monitoring (AI users)
• Cardiovascular risk modification (anthracycline/trastuzumab recipients)
• Psychosocial support, rehabilitation

---

10. Evidence & Guidelines

Key Guidelines

1. NICE NG101: Early and Locally Advanced Breast Cancer: Diagnosis and Management (2018, updated 2023)
2. NICE CG164: Familial Breast Cancer: Classification, Care and Managing Breast Cancer and Related Risks in People with a Family History of Breast Cancer (2013, updated 2019)
3. ESMO Clinical Practice Guidelines: Breast Cancer (2024)
4. NCCN Guidelines: Breast Cancer (Version 4.2024)
5. ABS (Association of Breast Surgery) Guidelines: UK consensus on surgical management

Landmark Trials

Screening

• Swedish Two-County Trial: Mammography screening reduced breast cancer mortality by 30% [8]
• UK Age Trial: Screening ages 40-49 showed mortality benefit after long-term follow-up

Surgery

• NSABP B-06: BCS + RT = Mastectomy for survival (20-year follow-up) [10]
• ACOSOG Z0011: Omitting ALND in 1-2 positive SLNs (BCS + RT) non-inferior [13]
• AMAROS: Axillary RT = ALND for regional control

Radiotherapy

• START A/B: Hypofractionated RT (15-16 fractions) = conventional 25 fractions [14]
• EORTC 22922-10925: Regional nodal RT improves DFS in node+ disease

Endocrine Therapy

• ATLAS/aTTom: Tamoxifen 10 years superior to 5 years [24]
• ATAC: Anastrozole superior to tamoxifen (postmenopausal ER+)
• SOFT/TEXT: Ovarian suppression + AI superior to tamoxifen (high-risk premenopausal) [25]

Anti-HER2 Therapy

• HERA: Adjuvant trastuzumab 1 year reduced recurrence 37% [26]
• CLEOPATRA: Pertuzumab + Trastuzumab + Docetaxel: median OS 56.5 months (metastatic HER2+) [6]
• DESTINY-Breast03: T-DXd superior to T-DM1 (metastatic HER2+) [27]

CDK4/6 Inhibitors

• PALOMA-2: Palbociclib + Letrozole: mPFS 27.6 months (1st-line metastatic ER+) [12]
• monarchE: Adjuvant abemaciclib improved iDFS in high-risk ER+ disease

Immunotherapy

• KEYNOTE-355: Pembrolizumab + chemo improved PFS in PD-L1+ metastatic TNBC [7]
• KEYNOTE-522: Neoadjuvant pembrolizumab increased pCR and EFS in TNBC

PARP Inhibitors

• OlympiA: Adjuvant olaparib improved iDFS in germline BRCA-mutated high-risk early breast cancer [28]

---

11. Patient/Layperson Explanation

What is Breast Cancer?

Breast cancer occurs when cells in the breast grow abnormally and form a lump (tumor). It's the most common cancer in women, affecting about 1 in 8 women during their lifetime. Most breast cancers are treatable, especially when found early.

What Are the Symptoms?

• A new lump in the breast or armpit
• Change in breast size or shape
• Skin changes: Dimpling, puckering, redness, or "orange peel" texture
• Nipple changes: Turning inward (inversion), discharge (especially bloody), or a rash
• Persistent pain in the breast (though most lumps are painless)

Important: Most breast lumps are NOT cancer, but any new lump should be checked by a doctor.

How is Breast Cancer Diagnosed?

Doctors use "triple assessment":

1. Clinical examination: Your doctor feels the breast and armpit for lumps
2. Imaging: Mammogram (X-ray of the breast) or ultrasound
3. Biopsy: Taking a small tissue sample with a needle to look at under a microscope

All three tests together are very accurate (> 95%) at diagnosing breast cancer.

What Are the Types of Breast Cancer?

Breast cancers are grouped by receptor status (proteins on cancer cells):

• ER/PR positive (70%): Responds to hormone therapy (tamoxifen)
• HER2 positive (15-20%): Responds to targeted therapy (Herceptin)
• Triple-negative (15%): Doesn't have ER, PR, or HER2; treated with chemotherapy

How is Breast Cancer Treated?

Treatment usually combines several approaches:

1. Surgery

• Lumpectomy (wide local excision): Removes the tumor and some surrounding tissue; breast is preserved
• Mastectomy: Removes the entire breast; reconstruction can be offered
• Lymph node removal: Sentinel node biopsy (removing 1-3 nodes) or full axillary clearance if cancer has spread

2. Radiotherapy

• High-energy X-rays to kill remaining cancer cells
• Usually given after lumpectomy (mandatory)
• Takes 3-5 weeks (daily treatments, Monday-Friday)

3. Drug Treatment

• Chemotherapy: Kills rapidly dividing cells; given before or after surgery
• Hormone therapy: Tamoxifen or aromatase inhibitors (for ER+ cancers); taken as tablets for 5-10 years
• Targeted therapy: Herceptin (trastuzumab) for HER2+ cancers; given as IV infusion

What About Screening?

• NHS Breast Screening Programme invites women aged 50-70 for a mammogram every 3 years
• Screening detects cancers early (often before you can feel a lump)
• Reduces breast cancer deaths by 20%

What is the Outlook?

• Early breast cancer (found when small, no spread): 9 in 10 women are alive 5 years later
• Advanced breast cancer (spread to other organs): Treatment focuses on controlling the disease and maintaining quality of life

What Can I Do?

• Attend screening when invited
• Know your breasts: Check them regularly; report any changes to your GP
• Maintain a healthy weight and limit alcohol (reduces risk)
• Breastfeed if possible (protective effect)

Where Can I Get Support?

• Breast Cancer Now: UK charity providing information and support (breastcancernow.org)
• Macmillan Cancer Support: Practical and emotional support (macmillan.org.uk)
• Your Breast Care Nurse: Specialist nurse who guides you through treatment

---

12. References

Guidelines

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. PMID: 38572751

2. Cancer Research UK. Breast cancer statistics. 2024. Available at: cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer

3. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752. PMID: 10963602

4. NICE. Early and locally advanced breast cancer: diagnosis and management (NG101). 2018, updated 2023. Available at: nice.org.uk/guidance/ng101

5. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386(10):942-950. PMID: 35263519

6. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer (CLEOPATRA). N Engl J Med. 2015;372(8):724-734. PMID: 25693012

7. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817-1828. PMID: 33278935

8. Tabár L, Vitak B, Chen TH, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011;260(3):658-663. PMID: 21712474

9. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. PMID: 36633525

10. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241. PMID: 12393820

11. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416. PMID: 28632866

12. Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer (PALOMA-2). N Engl J Med. 2016;375(20):1925-1936. PMID: 27959613

13. Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918-926. PMID: 28898379

14. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086-1094. PMID: 24055415

15. Giordano SH. Breast Cancer in Men. N Engl J Med. 2018;378(24):2311-2320. PMID: 29897847

16. Monticciolo DL, Newell MS, Moy L, et al. Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. J Am Coll Radiol. 2023;20(9):902-914. PMID: 37657780

17. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159-1168. PMID: 31474332

18. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360(9328):187-195. PMID: 12133652

19. Moore SC, Lee IM, Weiderpass E, et al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Intern Med. 2016;176(6):816-825. PMID: 27183032

20. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst. 1975;55(2):231-273. PMID: 169369

21. Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439-1445. PMID: 24185512

22. Loi S, Drubay D, Adams S, et al. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019;37(7):559-569. PMID: 30650045

23. Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22(3):515-523. PMID: 20603440

24. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816. PMID: 23219286

25. Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer (SOFT and TEXT). N Engl J Med. 2018;379(2):122-137. PMID: 29863451

26. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195-1205. PMID: 28215665

27. Cortés J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer (DESTINY-Breast03). N Engl J Med. 2022;386(12):1143-1154. PMID: 35172054

28. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer (OlympiA). N Engl J Med. 2021;384(25):2394-2405. PMID: 34081848

---